Kala Bio (KALA) Operating Income (2016 - 2026)
Kala Bio's (KALA) quarterly Operating Income came in at -$1.7 million in Q2 2026, up 84.39% year-over-year from -$933326.2 in Q2 2025, and up 4.5% quarter-over-quarter from -$1.8 million in Q1 2026.
Analysis
Kala Bio (KALA) Operating Income (2016 - 2026) Analysis & Trends
Kala Bio has disclosed Operating Income across 11 years of filings, most recently posting -$1.7 million for Q2 2026.
- In Q2 2026, Operating Income rose 84.39% year-over-year to -$1.7 million; the TTM figure through Jun 2026 stood at -$21.0 million (up 48.99% YoY), while the FY2025 annual figure was -$39.2 million, up 4.45% from the prior year.
- Operating Income came in at -$1.7 million for Q2 2026 at Kala Bio, up from -$1.8 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$1.7 million in Q2 2026 to a low of -$30.9 million in Q1 2022.
- Average Operating Income over 5 years is -$11.4 million, with a median of -$10.1 million recorded in 2024.
- Year-over-year, Operating Income slipped 14.82% in 2025 and surged 84.39% in 2026.
- Over 5 years, Operating Income stood at -$10.3 million in 2022, then gained by 6.17% to -$9.6 million in 2023, then gained by 1.66% to -$9.5 million in 2024, then dropped by 8.1% to -$10.2 million in 2025, then jumped by 83.17% to -$1.7 million in 2026.
- Per Business Quant data, the three most recent Operating Income figures were -$1.7 million in Q2 2026, -$1.8 million in Q1 2026, and -$10.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Kala Bio | 7.80 Mn | 7.80 Mn | - | -1.72 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.72 Mn |
| Mar 31, 2026 | -1.80 Mn |
| Dec 31, 2025 | -10.23 Mn |
| Sep 30, 2025 | -7.24 Mn |
| Jun 30, 2025 | -11.03 Mn |
| Mar 31, 2025 | -10.67 Mn |
| Dec 31, 2024 | -9.46 Mn |
| Sep 30, 2024 | -9.99 Mn |
| Jun 30, 2024 | -9.61 Mn |
| Mar 31, 2024 | -11.93 Mn |
| Dec 31, 2023 | -9.62 Mn |
| Sep 30, 2023 | -8.76 Mn |
| Jun 30, 2023 | -9.60 Mn |
| Mar 31, 2023 | -11.68 Mn |
| Dec 31, 2022 | -10.25 Mn |
| Sep 30, 2022 | -14.57 Mn |
| Jun 30, 2022 | -25.97 Mn |
| Mar 31, 2022 | -30.91 Mn |
| Dec 31, 2021 | -46.82 Mn |
| Sep 30, 2021 | -26.07 Mn |